 | Up a level |
Frontzek, F., Ziepert, M., Nickelsen, M., Altmann, B., Glass, B., Haenel, M., Truemper, L., Held, G., Bentz, M., Borchmann, P., Dreyling, M., Viardot, A., Kroschinsky, F., Metzner, B., Staiger, A. M., Horn, H., Ott, G., Rosenwald, A., Loeffler, M., Lenz, G. and Schmitz, N. (2020). 10-year follow-up of the R-MegaCHOEP trial: conditional survival analysis reveals 1-year progression-free survival as crucial prognostic factor for long-term outcome in young high-risk patients with aggressive B-cell lymphoma. Oncol. Res. Treat., 43 (SUPPL 4). S. 64 - 65. BASEL: KARGER. ISSN 2296-5262
Gaidzik, V., I, Weber, D., Paschka, P., Krieger, S., Kaumanns, A., Kroenke, J., Kapp-Schwoerer, S., Koehne, C-H, Horst, H-A, Schmidt-Wolf, I. G. H., Held, G., Kuendgen, A., Ringhoffer, M., Goetze, K., Kindler, T., Fiedler, W., Wattad, M., Corbacioglu, A., Bullinger, L., Schlegelberger, B., Thol, F., Heuser, M., Ganser, A., Schlenk, R. F., Doehner, H. and Doehner, K. (2015). DNMT3A mutations (DNMT3Amut) in acute myeloid leukemia (AML): monitoring of minimal residual disease (MRD). A study of the AML Study Group (AMLSG). Oncol. Res. Treat., 38. S. 7 - 8. BASEL: KARGER. ISSN 2296-5262
Murawski, N., Amam, J., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Poeschel, V. and Pfreundschuh, M. (2017). Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy. Oncol. Res. Treat., 40. S. 11 - 12. BASEL: KARGER. ISSN 2296-5262
Murawski, N., Pfreundschuh, M., Zeynalova, S., Poeschel, V., Haenel, M., Held, G., Schmitz, N., Viardot, A., Schmidt, C., Hallek, M., Witzens-Harig, M., Truemper, L., Rixecker, T. and Zwick, C. (2014). Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann. Oncol., 25 (9). S. 1800 - 1807. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Murawski, N., Poeschel, V., Ziepert, M., Altmann, B., Dreyling, M., Borchmann, P., Viardot, A., Luminari, S., Witzens-Harig, M., Dierlamm, J., Haenel, M., Truemper, L., Metzner, B., Lengfelder, E., Keller, U., Ruebe, C., Berdel, C., Schmitz, N., Held, G. and Pfreundschuh, M. (2018). Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. Oncol. Res. Treat., 41. S. 238 - 239. BASEL: KARGER. ISSN 2296-5262
Pfreundschuh, M., Christofyllakis, K., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Schneider, G., Ruebe, C., Hellwig, D., Poeschel, V. and Murawski, N. (2017). Radiotherapy to bulky disease PET-negative after immunochemotherapy can be spared in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL. Oncol. Res. Treat., 40. S. 11 - 12. BASEL: KARGER. ISSN 2296-5262
Thurner, L., Held, G., Poeschel, V, Berdel, C., Ott, G., Schmidt, C., Viardot, A., Engel-Riedel, W., Borchmann, P., Shpilberg, O., Witzens-Harig, M., Frickhofen, N., Nickelsen, M., Griesinger, F., Krammer-Steiner, B., Neubauer, A., Federico, M., Brown, de Nully P., Stilgenbauer, S., Murawski, N., Altmann, B., Truemper, L., Schmidberger, H., Ruebe, C., Fleckenstein, J., Schmitz, N., Loeffler, M. and Ziepert, M. (2020). Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: a subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA). Oncol. Res. Treat., 43 (SUPPL 4). S. 61 - 62. BASEL: KARGER. ISSN 2296-5262